Aptamer Group is a solutions company delivering transformational innovation to the global life sciences industry.
Working with 100% of the top 10 pharmaceutical companies, we partner with the world’s leading organisations to accelerate drug discovery, advance clinical development, and solve critical challenges in therapeutics, diagnostics, and bioprocessing.
Our proprietary Optimer® technology platform delivers next-generation synthetic binders that outperform traditional antibodies, enabling faster development timelines, superior performance, and enhanced specificity across a broader range of targets. This positions us to capture significant value in the $210bn global affinity ligand market.
Proven Performance with Global Pharma Leaders
We don’t just promise innovation, we deliver it. Our growing portfolio of partnerships with global industry leaders demonstrates both the versatility of our Optimer® platform and our ability to solve problems others cannot:
- Working with 100% of the top 10 pharma companies, our Optimer® binders have consistently outperformed commercial antibody-based reagents in head-to-head comparisons, supporting critical drug validation and development, as well as manufacture
- Delivering highly sensitive diagnostic reagents for an Alzheimer’s disease test where traditional antibodies previously failed, demonstrating our ability to access challenging targets beyond the reach of conventional approaches
- Collaborating with AstraZeneca to develop targeted siRNA delivery vehicles, addressing a critical challenge in a market valued at over $13 billion
- Multiple projects successfully progressing with Unilever, delivering novel solutions for next-generation consumer cosmetic innovation
Our repeat business model with top-tier pharmaceutical companies validates both our technology and execution capability. These partnerships span neurology, oncology, metabolism, and radiopharmaceuticals, creating pathways from initial reagent projects to high-value therapeutic development programs.
Our Vision: Science Unlimited
We remove the scientific limits holding back breakthrough discoveries. Where others see constraints in targets, speed, stability, selectivity, and scalability, we see opportunities to deliver better, faster solutions for our partners.
The Optimer® Advantage
Optimer® binders are engineered to address the fundamental limitations of antibodies and other affinity molecules. Our unique selection process delivers truly customised solutions tailored to each project’s specific application and performance requirements.
Key advantages include:
- Rapid development timelines, delivering from weeks to months, not years
- Batch consistency and cost-effective manufacturability
- Small molecular size enabling broader tissue penetration
- Robust performance across multiple in vitro formats
- Access to challenging targets beyond the reach of traditional antibodies
- Proven performance across therapeutics, critical reagents and diagnostics
Building Value Through Innovation
We’ve successfully delivered projects for global pharma companies, diagnostic developers, and leading research institutes, establishing royalty-bearing licenses and repeat partnerships. Our technology doesn’t just match existing solutions. In validated head-to-head comparisons with leading pharmaceutical partners, Optimer® binders have significantly outperformed commercial antibodies.
Every project we complete builds our proprietary IP portfolio, creating multiple revenue streams through licensing, royalties, and strategic partnerships. We’re not just advancing science, we are building a sustainable, high-value business that enables our partners to make faster, more informed decisions across the entire life sciences value chain.